Liver Disease Therapy

Double-conjugated oligonucleotides localize in liver better

Published in Gene Therapy Weekly, September 26th, 2002

by Sonia Nichols, senior medical writer - The old saying two heads are better than one could be used for describing a new liver-targeting therapy developed in the Netherlands.

Instead of using two heads, researchers have used two cholesteryl moieties to improve the uptake of phosphorothioate oligodeoxynucleotide (PS-ODN) by liver cells. The new construct drastically improves liver cell uptake without the expense of harming local nonhepatic tissues, according to the research investigators, who work at Leiden Amsterdam Center for Drug Research in Leiden.

In an earlier study, M.K. Bijsterbosch and colleagues found that a single cholesterol bound to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry